BofA reiterates Merck stock rating on Terns acquisition potential By Investing.com

Merck announced a definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion ($53.00/sh), a 31% premium to the 60-day VWAP (42% to the 90-day VWAP), and will take a $5.8 billion ($2.35/sh) in-process R&D charge in Q2. The deal targets TERN-701 (near Phase 3 readiness) and is positioned to bolster Merck's oncology lineup ahead of Keytruda loss of exclusivity in 2029-2031; BofA reiterated Buy ($132 PT) and Barclays maintained Overweight ($140 PT), while Morgan Stanley stayed Equalweight ($109) and H.C. Wainwright downgraded Terns to Neutral. The acquisition is expected to close in Q2 2026 per the report, has sector implications (Enliven up ~28%), and was not yet modeled by BofA pending close.

Analysis

Merck's latest bolt-on behaviour signals a deliberate shift from organic top-line reliance toward inorganic, stage-advanced supplementation — a pragmatic play to smooth the expected revenue cliff years out. That reduces binary exposure to any single blockbuster but increases execution and integration risk; every mid-cap tuck-in that looks “de-risked” on paper raises aggregate pipeline correlation and compresses ROIC unless integration synergies are realized within 12–36 months.

The lead BCR-ABL asset changes the competitive geometry in chronic myeloid leukemia: an allosteric approach can command premium pricing if it meaningfully addresses resistant genotypes, but Phase 3 is a binary lever that will re-rate the economics materially. Expect a multi-quarter to multi-year timeline for realization, with headline trial readouts and label breadth as the primary value inflection points; failure or bland differentiation would quickly erase any acquired goodwill and invite competitor countermeasures and price pressure from incumbents and generics.

Market microstructure will produce second-order winners and losers: small-cap oncology names that fit the acquirer's M&A sweet spot will get temporary multiple expansion, creating short-term takeover-arbitrage opportunities and volatility spikes in names with thin float. The biggest tactical risks are compressed spreads on subsequent deals (making future M&A expensive), near-term EPS noise from amortization/R&D accounting choices, and macro funding conditions that can widen financing costs — monitor 3–12 month rate moves and trial milestone calendars as the gating catalysts.

Key Decisions for Investors

• Long MRK via 12–18 month LEAP calls (allocate 2–3% portfolio): target asymmetric payoff to capture portfolio re-rating and later-stage pipeline progress. Risk: option premium loss; Reward: 30–50% upside if integration + phase‑3 readouts validate value. Cut: sell if implied vol-adjusted premium decays by 50% or if guidance is materially downgraded.
• Pair trade: long MRK (3% position) / short ELVN (2% position) for 1–3 month horizon to capture reversion after speculative M&A spillover. Rationale: MRK benefits structurally from portfolio diversification while ELVN is prone to takeover-fed froth; target net 15–25% tailwind on pair, stop if pair diverges >15% intramonth.
• Momentum arb on small-cap oncology targets (select names similar to recent buys): initiate small, diversified stakes (1% each across 3–5 names) to capture M&A rerating over 1–6 months. Risk-manage with 25–30% stop losses and tighten stops as rumor volume and bid indications increase; take profits incrementally if any single name trades >35% on credible deal chatter.
• Avoid outright equity exposure to the acquired company absent tight merger-arbitrage spread; if acting in arb desk capacity, only engage once financing, regulatory timelines, and termination fees are explicit — require an expected annualized arb spread >6% to compensate for regulatory/clinical tail risk.